New drug AK150 enters first human tests for tough cancers
NCT ID NCT07566247
First seen May 09, 2026 · Last updated May 21, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug called AK150 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan People's Hospital
Dongguan, Guangdong, 523000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.